Trial Profile
Phase 2 study of 2nd line dose-escalated nab-Paclitaxel for advanced or recurrent gastric cancer (KGSG1301)
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 01 Jun 2017
Price :
$35
*
At a glance
- Drugs Paclitaxel (Primary)
- Indications Adenocarcinoma; Gastric cancer
- Focus Therapeutic Use
- 29 May 2017 Status changed from recruiting to discontinued.
- 10 Oct 2016 New trial record